Received Jun 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
HCP called to state that the patient has missed their window to receive a second dose of GARDASIL 9 series according to the outlined schedule in the prescribing information.; No additional AE; This spontaneous report was received from a pharmacist referring to a 25-year-old patient, gender was not provided. Information regarding the patient's concurrent conditions, medical history, or concomitant medications was not provided. On an unknown date, reported as 1 or 2 years ago, the patient received the first dose of Human Papillomavieus 9-valent vaccine, recombinant suspension for injection (GARDASIL 9) injection 0,5 ml, administered for prophylaxis (route of administration, anatomical location, lot number and expiration date was not reported), the reporter mentioned that the patient not received their second dose. (Inappropriate schedule of product administration). There was not adverse event reported.